창상 치료용 바이오로직스 시장 평가 : 제품별, 상처별, 최종사용자별, 지역별 기회 및 예측(2017-2031년)

The global wound care biologics market is projected to witness a CAGR of 6.45% during the forecast period 2017-2031, growing from USD 2.01 billion in 2023 to USD 3.31 billion in 2031F. The global wound care biologics market consists of innovative treatments derived from natural sources or synthetic materials that are utilized in wound care procedures. These biologics include skin replacement products and stem cell therapies, which are essential for promoting tissue regeneration and wound healing. Bioengineered dermal substitutes and other biologic skin substitutes promote neovascularization and collagen formation, among other mechanisms that aid in the healing of chronic ulcers. To treat chronic wounds or diabetic foot ulcers with past histories and increased bioburden, topical agents derived from living organisms or cells are being used more often. Since biologic scaffolds form hydrogels that promote collagen synthesis and wound healing, their use in treating chronic non-healing wounds has shown effective results.

Wound care biologics are widely used in the management and treatment of burns, traumatic injuries, and foot ulcers. Anti-infective wound care products have demonstrated effectiveness in treating wounds with infection, such as diabetic foot ulcers. For long-standing foot ulcers or chronic wounds, biologic interventions have been clinically effective. The global wound care biologics market is being driven significantly by the increasing prevalence of burn injuries, traumatic wounds, and foot ulcers. Other factors that are driving the market growth are technological advancements, a growing geriatric population, and an increasing number of road accidents.

For instance, Biologics company Tides Medical announced the launch of a new product in July 2022, Artacent AC, a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds. Artacent AC is three times stronger and two times thicker than traditional dual-layer products, making it easier to handle and apply to wound sites. To provide physicians with an advanced amniotic skin graft option, Tides developed Artacent AC, which consists of three layers (amnion-chorion-amnion) as opposed to the conventional two (amnion-amnion).

Increasing Prevalence of Diabetic Foot Ulcer and Burn Injuries

The global wound care biologics market is being driven largely due to the rising incidence of burn injuries and diabetic foot ulcers. Diabetic foot ulcers are among the associated complications that are becoming more common as the prevalence of diabetes increases globally. Every year, 1.6 million Americans and 18.6 million people worldwide suffer from diabetic foot ulcers. About 1% of diabetic patients have their feet amputated, and 5% of patients develop foot ulcers. Over the past few years, it has been estimated that 1-4% of diabetic patients develop foot ulcers each year. Burns are a public health concern since they are responsible for 180,000 deaths globally each year. Almost two-thirds of these are found in the African and South-East Asian regions, with the majority occurring in low- and middle-income countries. Advanced therapies such as skin substitutes and growth factors, which are a part of wound care biologics, are becoming more and more popular for their ability to boost healing and reduce complications. As a result of this increased awareness and the growing need for innovative and efficient wound care solutions, the market for wound care biologics has been positioned as essential to solving the problems associated with burn injuries and diabetic foot ulcers.

Growing Number of Road Accidents

Global traffic accident rates are rising, which is one of the key factors propelling the global wound care biologics market growth. Road accidents frequently cause a range of injuries, from small cuts to severe wounds, necessitating the use of cutting-edge wound care techniques. Demand for wound care biologics is being driven by the growing need for quick and efficient wound healing as well as a greater understanding of the clinical benefits of biologic-based treatments. Advanced therapies, such as growth factors and tissue-engineered products, are essential for accelerating the healing process and reducing the likelihood of complications following traumatic injuries. An estimated 1.19 million people lose their lives in traffic-related incidents each year. For kids and young adults aged 5 to 29, traffic accidents are the main cause of death. Despite having about 60% of the world's vehicles, low- and middle-income countries account for 92% of all road fatalities worldwide.

Technological Advancements

Technological advancements in the global wound care biologics market are revolutionizing the landscape of wound care management. Innovative approaches involve the utilization of growth factors, stem cells, and cytokines to stimulate tissue regeneration and accelerate the healing process. Biological skin substitutes, leveraging tissue engineering and 3D printing technologies, are providing better alternatives to traditional grafts, offering improved compatibility and functionality. Topical agents are benefiting from nanotechnology and sustained release formulations, improving their efficacy in infection control and wound healing.

For instance, in January 2023, Kerecis introduced its GraftGuide fish-skin product line, which addresses the difficulties associated with burn healing. GraftGuide Mano is made to adapt to the shape of a hand. Surgeons do not need to customize the graft because the product can easily cover the three-dimensional structure of the hand. This reduces the surgical time and eliminates the need for numerous grafts and bulky fixation.

Dominance of Hospitals

Due to the complex nature of the hospital environment, wound care is mostly used in hospitals as compared to ambulatory surgical centers and burn care centers. Wounds of varying degrees of severity are more common in hospitals because they typically handle a wide variety of medical cases, including complicated surgeries, trauma, and chronic conditions. Hospitals are equipped with a comprehensive infrastructure that facilitates access to a wide range of wound care resources, advanced diagnostic tools, and specialized medical professionals. Hospitals are the main hub for comprehensive wound care management because they are equipped to handle acute cases that may need intensive care and continuous monitoring. This allows medical professionals to address a wide range of wounds, from severe injuries to post-surgical incisions.

North America Dominates the Global Wound Care Biologics Market

North America's dominance in the global wound care biologics market is being driven by various factors. The region has a well-established healthcare infrastructure that readily adopts and integrates advanced medical technologies. In addition, a high prevalence of chronic conditions such as diabetes and vascular diseases, has led to an increased demand for advanced wound care solutions, positioning biologics as a critical component for treatment protocols. The regulatory environment and reimbursement policies in the United States and Canada further facilitate the widespread adoption of innovative wound care biologics.

In October 2023, MTF Biologics announced that the FDA granted an IDE (Investigational Device Exemption) to initiate a clinical study verifying the efficacy and safety of FlexHD Pliable for breast reconstruction based on implants. This is the first IDE approval for a human acellular dermal matrix for breast reconstruction granted by the FDA.

Future Market Scenario (2024-2031F)

Allografts and xenografts are increasingly being used as skin substitutes beyond just dressings, indicating a shift towards more advanced biologic skin substitutes.

Bioengineered skin substitutes are gaining prominence as an alternative approach to treating large skin defects caused by burns or trauma. These substitutes can be classified based on their chemical composition, scaffold material, and skin components.

Incorporating functional moieties into skin substitutes is a growing trend. For instance, antimicrobials and wound healing agents are being integrated into bioengineered smart skin substitutes. These functionalized substitutes aim to enhance wound healing outcomes and prevent infections.

Key Players Landscape and Outlook

The global wound care biologics market is characterized by a competitive landscape with key players driving innovation and market expansion. These market players are investing in R&D to improve product efficacy, patient comfort, and dosage precision. Partnerships and collaborations between medical device and pharmaceutical companies are being formed with the aim of the development of advanced wound care products that can be integrated with smartphones and applications.

For instance, in May 2023, the Acellular dermal matrix, a natural soft tissue reconstruction solution that AlloSource announced to provide long-term structural support, AlloMend Duo ADM was developed to assist surgeons in reconstructing soft tissue defects. A scaffold for cell repopulation and natural host tissue regeneration is provided by the deep reticular dermal allograft, which blends in with the surrounding tissue.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2.By Product
  • 4.2.1. Biological Skin Substitutes
  • 4.2.2. Topical Agents
• 4.3.By Wound
  • 4.3.1. Ulcers
  • 4.3.2. Surgical & Traumatic Wounds
  • 4.3.3. Burns
• 4.4.By End-user
  • 4.4.1. Hospitals & Clinics
  • 4.4.2. Ambulatory Surgical Centers
  • 4.4.3. Burn Care Centers & Wound Clinic
• 4.5.By Region
  • 4.5.1.North America
  • 4.5.2.Europe
  • 4.5.3.Asia-Pacific
  • 4.5.4.South America
  • 4.5.5.Middle East and Africa
• 4.6.By Company Market Share (%), 2023

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Product
    • 5.1.2.1.Biological Skin Substitutes
    • 5.1.2.2.Topical Agents
  • 5.1.3.By Wound
    • 5.1.3.1.Ulcers
    • 5.1.3.2.Surgical & Traumatic Wounds
    • 5.1.3.3.Burns
  • 5.1.4.By End-user
    • 5.1.4.1.Hospitals & Clinics
    • 5.1.4.2.Ambulatory Surgical Centers
    • 5.1.4.3.Burn Care Centers & Wound Clinic
  • 5.1.5.United States*
    • 5.1.5.1.Market Size & Forecast
    • 5.1.5.1.1.By Value
    • 5.1.5.1.2.By Volume
    • 5.1.5.2.By Product
    • 5.1.5.2.1.Biological Skin Substitutes
    • 5.1.5.2.2.Topical Agents
    • 5.1.5.3.By Wound
    • 5.1.5.3.1.Ulcers
    • 5.1.5.3.2.Surgical & Traumatic Wounds
    • 5.1.5.3.3.Burns
    • 5.1.5.4.By End-user
    • 5.1.5.4.1.Hospitals & Clinics
    • 5.1.5.4.2.Ambulatory Surgical Centers
    • 5.1.5.4.3.Burn Care Centers & Wound Clinic
  • 5.1.6.Canada
  • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3.Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4.South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5.Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. U.A.E.
  • 5.5.3. South Africa

6.Market Mapping, 2023

• 6.1.By Product
• 6.2.By Wound
• 6.3.By End-user
• 6.4.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Patent Landscape
• 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Smith & Nephew Plc
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Integra LifeSciences Corporation
• 13.3.Stryker Corporation
• 13.4.Organogenesis Inc
• 13.5.MixMedx Inc
• 13.6.Kerecis Limited
• 13.7.Molnlycke Healthcare AB
• 13.8.Lynch Biologics
• 13.9.Skye Biologics Holdings LLC
• 13.10.Marine Polymer Technologies Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer